ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
1Q2023 Total Revenues of $57 Million, a 96% Y-o-Y Increase 1Q2023 Net Loss of $6.8 Million, a 73% Y-o-Y Improvement Achieved Milestone First-Time Positive Adjusted EBITDA (1), Totaling $2.5 Million, Earlier Than Forecasted FY2023 Total Revenue Now Expected …